C9093 Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg

Short descriptor: Inj., susvimo, 0.1 mg

⚠ Terminated HCPCS Level II 2026
Terminated Code
C9093 was terminated as of 2022-06-30 and should not be reported for dates of service after that date. This page is retained for historical reference.
Open C9093 in the app →

Look up C9093 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

C9093 is the HCPCS Level II code for Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg (2026). It belongs to Section C — Outpatient PPS (Hospital). Under Medicare, its coverage status is: Special coverage instructions apply. Part B pricing methodology: Statute.

Classification & CMS Attributes

Medicare Coverage
Special coverage instructions apply (code D)
Part B Pricing
Statute (indicator 53)
Type of Service
Other medical items or services
Effective Date
2022-07-01
Termination Date
2022-06-30
2026 Maintenance
No change this year

References

Cite This Page

Reference C9093 with the canonical source and edition:

C9093 — Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/C9093

Canonical URL: https://icd10codingpro.com/hcpcs-codes/C9093

Related Codes in Section C

Browse all HCPCS Level II sections →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2026-01-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial